0 131

Cited 0 times in

First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.

DC Field Value Language
dc.contributor.author신상준-
dc.date.accessioned2023-06-02T00:54:37Z-
dc.date.available2023-06-02T00:54:37Z-
dc.date.issued2022-02-
dc.identifier.issn0732-183X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194522-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherAmerican Society of Clinical Oncology-
dc.relation.isPartOfJOURNAL OF CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleFirst-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYohann Loriot-
dc.contributor.googleauthorPetros Grivas-
dc.contributor.googleauthorRonald De Wit-
dc.contributor.googleauthorArjun Vasant Balar-
dc.contributor.googleauthorArlene O. Siefker-Radtke-
dc.contributor.googleauthorJakub Zolnierek-
dc.contributor.googleauthorTibor Csoszi-
dc.contributor.googleauthorSang Joon Shin-
dc.contributor.googleauthorSe Hoon Park-
dc.contributor.googleauthorVagif Atduev-
dc.contributor.googleauthorMahmut Gumus-
dc.contributor.googleauthorYu-Li Su-
dc.contributor.googleauthorSaziye Burcak Karaca-
dc.contributor.googleauthorHernan Cutuli-
dc.contributor.googleauthorMehmet Nahit Sendur-
dc.contributor.googleauthorCalvin Jia-
dc.contributor.googleauthorKaren O'Hara-
dc.contributor.googleauthorSonia Franco-
dc.contributor.googleauthorNobuaki Matsubara-
dc.identifier.doi10.1200/JCO.2022.40.6_suppl.432-
dc.contributor.localIdA02105-
dc.relation.journalcodeJ01331-
dc.identifier.eissn1527-7755-
dc.identifier.urlhttps://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.432-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.affiliatedAuthor신상준-
dc.citation.volume40-
dc.citation.number6_suppl-
dc.citation.startPage432-
dc.identifier.bibliographicCitationJOURNAL OF CLINICAL ONCOLOGY, Vol.40(6_suppl) : 432, 2022-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.